15 MBq/kg Betalutin

DRUG2 trials

Sponsors

Nordic Nanovector

Conditions

Follicular LymphomaNon Hodgkin LymphomaNon-Hodgkin LymphomaRelapsed Follicular Lymphoma

Phase 1

A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma

CompletedNCT01796171

Nordic NanovectorFollicular Lymphoma, Non-Hodgkin Lymphoma

Start: 2012-12-31End: 2022-10-27Updated: 2024-06-21

Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL

CompletedNCT03806179

Nordic NanovectorFollicular Lymphoma, Non Hodgkin Lymphoma, Relapsed Follicular Lymphoma

Start: 2018-10-04End: 2022-08-08Updated: 2023-12-22

Related Papers

System-Level Barriers to Uptake of Existing and Novel Radioimmunotherapy for People with Lymphoma

Blood2021-11-05

FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of <sup>177</sup>Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma.

2020-11-167 citations

Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma

Blood Advances2020-09-0244 citations